{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:34:38Z","timestamp":1765370078133,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10147-022-02246-1","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:57:20Z","timestamp":1665406640000},"page":"1874-1880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study)"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-3333","authenticated-orcid":false,"given":"Tadahiro","family":"Shoji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Takatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kagabu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Shigeto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Seino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Shigeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Kaiho-Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenori","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"2246_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"2246_CR2","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"2246_CR3","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496","journal-title":"N Engl J Med"},{"key":"2246_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/IGC.0000000000000836","volume":"27","author":"AM Oza","year":"2017","unstructured":"Oza AM, Selle F, Davidenko I et al (2017) Efficacy and safety of bevacizumab-containing therapy in newly diagnosed ovarian cancer: ROSiA single-arm phase 3B study. Int J Gynecol Cancer 27:50\u201358","journal-title":"Int J Gynecol Cancer"},{"key":"2246_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"2246_CR6","unstructured":"Japan Clinical Oncology Group (2010) Common toxicity criteria for adverse events version 4.0 Japanese translation (CTCAE-JCOG). http:\/\/www.jcog.jp\/doctor\/tool\/ctcaev4.html. Accessed Mar 1 2019"},{"key":"2246_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48:452\u2013458","journal-title":"Bone Marrow Transpl"},{"key":"2246_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ygyno.2017.04.011","volume":"146","author":"MA Bookman","year":"2017","unstructured":"Bookman MA, Tyczynski JE, Espirito JL et al (2017) Impact of primary platinum-free interval and BRCA1\/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol 146:58\u201363","journal-title":"Gynecol Oncol"},{"key":"2246_CR9","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N et al (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol 23:2605\u20132612","journal-title":"Ann Oncol"},{"key":"2246_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ygyno.2016.05.017","volume":"142","author":"M Petrillo","year":"2016","unstructured":"Petrillo M, Amadio G, Salutari V et al (2016) Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study. Gynecol Oncol 142:231\u2013236","journal-title":"Gynecol Oncol"},{"key":"2246_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10147-018-1319-y","volume":"24","author":"S Komiyama","year":"2019","unstructured":"Komiyama S, Kato K, Inokuchi Y et al (2019) Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Int J Clin Oncol 24:103\u2013114","journal-title":"Int J Clin Oncol"},{"key":"2246_CR12","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari KS, Burger RA, Enserro D et al (2019) final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 37:2317\u20132328","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"2246_CR13","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2021.39.15_suppl.5501","volume":"39","author":"J Pfister","year":"2021","unstructured":"Pfister J, Joly F, Kristensen G et al (2021) Optimal treatment duration of bevacizumab combined with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer: a multicenter open-label randomized 2-arm phase 3 ENGOT\/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17\/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890). J Clin Oncol 39(Suppl 15):5501","journal-title":"J Clin Oncol"},{"key":"2246_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168707","volume":"11","author":"A Matsuoka","year":"2016","unstructured":"Matsuoka A, Maeda O, Mizutani T et al (2016) Bevacizumab exacerbates paclitaxel-induced neuropathy: a retrospective cohort study. PLoS One 11:e0168707","journal-title":"PLoS One"},{"key":"2246_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10549-011-1685-x","volume":"129","author":"K Aogi","year":"2011","unstructured":"Aogi K, Masuda N, Ohno S et al (2011) First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 129:829\u2013838","journal-title":"Breast Cancer Res Treat"},{"key":"2246_CR16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N et al (2021) Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 22:1721\u20131731","journal-title":"Lancet Oncol"},{"key":"2246_CR17","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391\u20132402","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-022-02246-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:01:19Z","timestamp":1669420879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-022-02246-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2246"],"URL":"https:\/\/doi.org\/10.1007\/s10147-022-02246-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors of this manuscript has any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}